Smith & Nephew demonstrated robust financial momentum in 2025, achieving $6.16 billion in revenue and a 51.7% increase in net income supported by innovative product launches and operational restructuring. The company’s disciplined portfolio rationalization, particularly within Orthopaedics, alongside the acquisition of Integrity Orthopaedics, positions it for enhanced market penetration and margin expansion. Capital allocation remains balanced with meaningful dividends and share buybacks, while the commercial business restructuring fosters accountability and growth. Regulatory and integration risks persist, but the company’s innovation pipeline and strategic execution are key future catalysts.